文献速递衰弱、肌少症与跌倒老年慢病共病管理

按衰弱状态评估COVID-19 mRNA疫苗对退伍军人住院和死亡的保护效果:德尔塔变异株流行期间回顾性队列研究

COVID-19 mRNA vaccine effectiveness against hospitalisation and death in veterans according to frailty status during the SARS-CoV-2 delta (B.1.617.2) variant surge in the USA: a retrospective cohort study.
PubMed 文献 · Lancet Healthy Longev · 2022-08-01

该回顾性队列研究纳入57 784名SARS-CoV-2检测阳性的美国退伍军人,按衰弱状态分为健壮、衰弱前期和衰弱三组,评估COVID-19 mRNA疫苗对30天内住院和全因死亡的保护效果。结果显示,疫苗对住院的保护效果在健壮组为65%、衰弱前期组54%、衰弱组36%;对全因死亡的保护效果在健壮组和衰弱前期组均为79%,衰弱组为68%。

要点

  • 衰弱患者疫苗对COVID-19住院的保护效果低于非衰弱患者。
  • 衰弱组疫苗对全因死亡的保护效果亦低于健壮和衰弱前期组。
  • 未来疫苗效果研究应纳入衰弱评估并积极招募衰弱老年人。

核心结论

  • 与非衰弱患者相比,衰弱患者接种COVID-19疫苗后对COVID-19相关住院和全因死亡的保护水平较低。

研究设计与样本

  • 回顾性队列研究,数据来自美国退伍军人健康管理局设施和VA COVID-19共享数据资源。
  • 纳入2021年7月25日至9月30日期间SARS-CoV-2检测阳性且无既往阳性记录的19岁及以上退伍军人,共57 784人。
  • 按衰弱状态分为健壮(28 497人)、衰弱前期(16 737人)和衰弱(12 550人)三组。

主要发现

  • 30天内共发生2 577例全因死亡(疫苗接种组676例,未接种组1 901例)和7 857例COVID-19相关住院(疫苗接种组2 749例,未接种组5 108例)。
  • 疫苗对COVID-19相关住院的保护效果:健壮组65%(95%CI 61-69),衰弱前期组54%(48-58),衰弱组36%(30-42)。
  • 疫苗对全因死亡的保护效果:健壮组79%(95%CI 74-84),衰弱前期组79%(75-83),衰弱组68%(63-71)。

临床怎么用

  • 对衰弱老年人接种COVID-19疫苗后仍需关注其住院和死亡风险,不能因接种而放松防护和监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Studies have shown that COVID-19 vaccination is effective at preventing infection and death in older populations. However, whether vaccination effectiveness is reduced in patients with frailty is unclear. We aimed to compare vaccine effectiveness against hospitalisation and death after COVID-19 during the surge of the delta (B.1.617.2) variant of SARS-CoV-2 according to patients' frailty status. METHODS: In this retrospective cohort study, we used data derived from the US Veterans Health Administration (VHA) facilities and the US Department of Veterans Affairs (VA) COVID-19 Shared Data Resource, which contains information from the VA National Surveillance Tool, death certificates, and National Cemetery Administration. We included veterans aged 19 years or older who tested positive for SARS-CoV-2 using RT-PCR or antigen tests between July 25 and Sept 30, 2021, with no record of a previous positive test. Deaths were identified through VHA facilities, death certificates, and National Cemetery Administration data available from VA databases. We also retrieved data including sociodemographic characteristics, medical conditions diagnosed at baseline, frailty score, and vaccination information. The primary outcomes were COVID-19-associated hospitalisations and all-cause deaths at 30 days from testing positive for SARS-CoV-2. The odds ratio (OR) for COVID-19-associated hospitalisation and hazard ratio (HR) for death of vaccinated patients compared with the unvaccinated patients were estimated according to frailty categories of robust, pre-frail, or frail. Vaccine effectiveness was estimated as 1 minus the OR for COVID-19-associated hospitalisation, and 1 minus the HR for death. FINDINGS: We identified 57 784 veterans (mean age 57·5 years [SD 16·7], 50 642 [87·6%] males, and 40 743 [70·5%] White people), of whom 28 497 (49·3%) were categorised as robust, 16 737 (29·0%) as pre-frail, and 12 550 (21·7%) as frail. There were 2577 all-cause deaths (676 [26·2%] in the vaccinated group and 1901 [73·8%] in the unvaccinated group), and 7857 COVID-19-associated hospitalisations (2749 [35·0%] in the vaccinated group and 5108 [65·0%] in the unvaccinated group) within 30 days of a positive SARS-CoV-2 test. Vaccine effectiveness against COVID-19-associated hospitalisation within 30 days of a positive SARS-CoV-2 test was 65% (95% CI 61-69) in the robust group, 54% (48-58) in the pre-frail group, and 36% (30-42) in the frail group. By 30 days of a positive SARS-CoV-2 test, the vaccine effectiveness for all-cause death was 79% (95% CI 74-84) in the robust group, 79% (75-83) in the pre-frail group, and 68% (63-71) in the frail group. INTERPRETATION: Compared with non-frail patients (pre-frail and robust), those with frailty had lower levels of vaccination protection against COVID-19-associated hospitalisation and all-cause death. Future studies investigating COVID-19 vaccine effectiveness should incorporate frailty assessments and actively recruit older adults with frailty. FUNDING: Miami VA Healthcare System Geriatric Research Education and Clinical Center.

来源:Lancet Healthy Longev,查看原文。版权归原作者所有。

引用

  1. Tang F, Hammel IS, Andrew MK, et al. COVID-19 mRNA vaccine effectiveness against hospitalisation and death in veterans according to frailty status during the SARS-CoV-2 delta (B.1.617.2) variant surge in the USA: a retrospective cohort study. Lancet Healthy Longev. 2022. PMID: 35935474. doi:10.1016/S2666-7568(22)00166-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。